Phesgo and Tecentriq Performance and Approvals
NME submissions and their additional indications
Projects in phase II and III
Columvi (glofitamab)+
RG6026
RG6058
chemo
1L ctDNA+ high risk DLBCL
tiragolumab + T
1L PD-L1+ cervical
RG6330
divarasib
(KRAS G12 C)
2L NSCLC
RG7314
Roche
balovaptan
post-traumatic stress
disorder
astegolimab
RG6149
(anti-ST2)
New Molecular Entity (NME)
Additional Indication (Al)
Oncology/Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
cancer
COPD
RG7816
alogabat
(GABA Aa5 PAM)
ASD
tiragolumab +T
RG6058 locally adv esophageal
RG62991
Other
ASO factor B
IgA nephropathy
RG7845
fenebrutinib
RMS
cancer
RG6058
tiragolumab + T
1L non-sq NSCLC
RG6341
NME
chronic cough
RG7845
fenebrutinib
PPMS
ā Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU
RG7854/
tiragolumab +T
PDS-Port Delivery System with ranibizumab
RG6058
1L PD-L1+ MSCCHN
*First filed in China
RG6346/
RG6084
ruzotolimod (TLR7 ago [3])/
xalnesiran (siRNA)/ PDL1 LNA
HBV
RG7906
ralmitaront
schizophrenia
1IONIS managed
tiragolumab+T+/-
RG6058
chemo
RG1662
NSCLC neoadj/adj
basmisanil
Dup 15q syndrome
RG7935
prasinezumab
Parkinson's
RG6107
crovalimab
sickle cell disease
tominersen
RG6042
RG6179
Huntington's
anti-IL-6
UME
tiragolumab + T
tobemstomig
RG6058
1L PD-L1+ NSCLC
RG6139
(PD1xLAG3)
RG6100
semorinemab
Alzheimer's
anti-IL-6
RG6179
DME
solid tumors
tiragolumab +T
RG6058
1L esophageal cancer
(CN)
RG6026
Columvi
(glofitamab) + chemo
2L DLBCL
giredestrant
trontinemab
RG6171
(SERD)
RG6102
RG62991
Alzheimer's
1L ER+/HER2- MBC
RG6107
crovalimab*
PNH (EU, US)
RG6058
tiragolumab + T
Stage III unresectable
giredestrant
latent myostatin +
RG6171
(SERD)
RG6237
1L NSCLC
ER+ BC adj
Evrysdi
SMA
RG6321
ASO factor B
geographic atrophy
Susvimo
(PDS)
WAMD, 36-week refill
Susvimo
inavolisib
RG6321
(PDS)
DME (US)
RG6114
(mPI3K alpha inh)
1L HR+ BC
RG6107
crovalimab
aHUS
giredestrant (SERD) +
RG6171
Phesgo
RG6237
latent myostatin
FSHD
OpRegen
RG6501
1L ER+/HER2+ BC
geographic atrophy
RG6321
Susvimo
(PDS)
DR (US)
delandistrogene
RG6356
moxeparvovec
RG6321
(SRP-9001) DMD (EU)
Susvimo
(PDS)
WAMD, DME, DR (EU)
RG6180
autogene cevumeran
1L melanoma
RG6416
bepranemab
Alzheimer's
2023
2024
2025
2026 and beyond
vicasinabin
RG7774 (CB2 receptor agonist)
DR
Status as of April 26, 2023
55View entire presentation